VAPI is an acronym that stands for Vaping-Associated Pulmonary Injury. It refers to a condition characterized by severe lung damage and respiratory symptoms that are linked to the use of electronic cigarettes or vaping products. This term gained prominence during the surge of vaping-related illnesses reported across various countries.
VAPI typically manifests as symptoms such as shortness of breath, coughing, chest pain, nausea, fever, and fatigue. In some cases, individuals affected by VAPI may also experience gastrointestinal symptoms, such as vomiting or diarrhea. The severity of the condition can vary, ranging from mild respiratory distress to life-threatening lung injury requiring mechanical ventilation.
The exact cause of VAPI is still under investigation; however, it is believed to be related to the inhalation of harmful substances present in vaping products. These substances may include toxic chemicals, heavy metals, and other potentially dangerous compounds that could be present in e-liquids or aerosolized materials.
The diagnosis of VAPI often involves ruling out other respiratory conditions, such as infection or lung disease, through imaging tests, laboratory evaluations, and examination of the patient's medical history. Treatment for VAPI primarily focuses on supportive care, including oxygen therapy and monitoring of lung function. In severe cases, hospitalization and intensive care treatment may be necessary.
Due to the growing concern about the health risks associated with vaping, public health agencies have issued warnings and recommendations to limit or cease the use of electronic cigarettes and vaping products, especially among young individuals and individuals with pre-existing lung conditions.
